PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
27919234-3	2016	Combining iCBT with traditional face-to-face (ftf) consultations in a blended format (B-CBT) may produce a new treatment format with multiple benefits from both traditional CBT and iCBT such as individual adaptation, lower costs than traditional therapy, wide geographical and temporal availability, and possibly lower threshold to implementation.	icbt	10-14	opsin 1, short wave sensitive	Homo sapiens	88-91
30873251-23	2019	For adults with mild to moderate major depression, guided iCBT was associated with increases in both quality-adjusted survival (0.04 quality-adjusted life-years [QALYs]) and cost ($1,257), yielding an ICER of $31,575 per QALY gained when compared with usual care.	icbt	58-62	cAMP responsive element modulator	Homo sapiens	201-205
30873251-24	2019	In adults with anxiety disorders, guided iCBT was also associated with increases in both quality-adjusted survival (0.03 QALYs) and cost ($1,395), yielding an ICER of $43,214 per QALY gained when compared with unguided iCBT.	icbt	41-45	cAMP responsive element modulator	Homo sapiens	159-163
30873251-25	2019	In this population, guided iCBT was associated with an ICER of $26,719 per QALY gained when compared with usual care.	icbt	27-31	cAMP responsive element modulator	Homo sapiens	55-59
29805521-6	2018	The present study aimed to evaluate the prognostic value of CD103+ cells in patients with RCC and their potential role in enhancing the effect of ICBT in RCC.	icbt	146-150	integrin subunit alpha E	Homo sapiens	60-65
29805521-10	2018	The expansion of CD103+ cells promoted the effects of ICBT in the RCC xenograft mouse model, while depletion of CD103+ cells had the opposite effect.	icbt	54-58	integrin alpha E, epithelial-associated	Mus musculus	17-22
29805521-13	2018	Thus, the expansion of CD103+ cells may increase the efficacy of ICBT in patients with RCC.	icbt	65-69	integrin subunit alpha E	Homo sapiens	23-28
29971153-2	2018	Aims: To develop and evaluate the feasibility and preliminary efficacy of an ICBT programme for young children with obsessive-compulsive disorder (OCD), named BIP OCD Junior.	icbt	77-81	heat shock protein family A (Hsp70) member 5	Homo sapiens	159-162
27919234-3	2016	Combining iCBT with traditional face-to-face (ftf) consultations in a blended format (B-CBT) may produce a new treatment format with multiple benefits from both traditional CBT and iCBT such as individual adaptation, lower costs than traditional therapy, wide geographical and temporal availability, and possibly lower threshold to implementation.	icbt	181-185	opsin 1, short wave sensitive	Homo sapiens	88-91
22608115-7	2013	RESULTS: The main ICER was -$1244, indicating the societal economic gain for each additional case of remission when administering ICBT.	icbt	130-134	cAMP responsive element modulator	Homo sapiens	18-22
25781229-8	2015	From multivariate BOLD responses in the dorsal anterior cingulate cortex (dACC) together with the amygdala, we were able to predict long-term response rate of iCBT with an accuracy of 92% (confidence interval 95% 73.2-97.6).	icbt	159-163	Acetyl-CoA carboxylase	Drosophila melanogaster	74-78
25781229-11	2015	Thus, BOLD response patterns in the fear-expressing dACC-amygdala regions were highly predictive of long-term treatment outcome of iCBT, and the initial coupling between these regions differentiated long-term responders from nonresponders.	icbt	131-135	Acetyl-CoA carboxylase	Drosophila melanogaster	52-56
15204169-2	2004	Since tissue factor (TF) is an important mediator of arterial thrombosis, we tested the hypothesis that ICBT results in persistently augmented TF expression.	icbt	104-108	coagulation factor III, tissue factor	Sus scrofa	6-19
15204169-2	2004	Since tissue factor (TF) is an important mediator of arterial thrombosis, we tested the hypothesis that ICBT results in persistently augmented TF expression.	icbt	104-108	coagulation factor III, tissue factor	Sus scrofa	21-23
15204169-2	2004	Since tissue factor (TF) is an important mediator of arterial thrombosis, we tested the hypothesis that ICBT results in persistently augmented TF expression.	icbt	104-108	coagulation factor III, tissue factor	Sus scrofa	143-145
15204169-5	2004	ICBT-treated arteries had higher TF antigen and activity at all time-points compared to BI arteries (Western blot: 16 571 +/- 2090 vs 10 135 +/- 2939 densitometric units, p = 0.001; ELISA: 0.42 +/- 0.13 nM vs 0.25 +/- 0.14 nM, p = 0.001; TF activity assay: 0.303 +/- 0.11 nM vs 0.18 +/- 0.07 nM, p = 0.01; immunohistochemical staining: 30.6 +/- 6.6% vs 11.5% +/- 3.2%, p = 0.01).	icbt	0-4	coagulation factor III, tissue factor	Sus scrofa	33-35
15204169-5	2004	ICBT-treated arteries had higher TF antigen and activity at all time-points compared to BI arteries (Western blot: 16 571 +/- 2090 vs 10 135 +/- 2939 densitometric units, p = 0.001; ELISA: 0.42 +/- 0.13 nM vs 0.25 +/- 0.14 nM, p = 0.001; TF activity assay: 0.303 +/- 0.11 nM vs 0.18 +/- 0.07 nM, p = 0.01; immunohistochemical staining: 30.6 +/- 6.6% vs 11.5% +/- 3.2%, p = 0.01).	icbt	0-4	coagulation factor III, tissue factor	Sus scrofa	238-240
15204169-6	2004	TF expression increased following BI, increased further following ICBT, and persisted for the duration of the study.	icbt	66-70	coagulation factor III, tissue factor	Sus scrofa	0-2
15204169-7	2004	We conclude that TF expression increases after BI, but is further increased and persists for a longer duration following ICBT, suggesting that a TF-mediated mechanism may play a role in late thrombosis following ICBT.	icbt	121-125	coagulation factor III, tissue factor	Sus scrofa	17-19
15204169-7	2004	We conclude that TF expression increases after BI, but is further increased and persists for a longer duration following ICBT, suggesting that a TF-mediated mechanism may play a role in late thrombosis following ICBT.	icbt	121-125	coagulation factor III, tissue factor	Sus scrofa	145-147
15204169-7	2004	We conclude that TF expression increases after BI, but is further increased and persists for a longer duration following ICBT, suggesting that a TF-mediated mechanism may play a role in late thrombosis following ICBT.	icbt	212-216	coagulation factor III, tissue factor	Sus scrofa	17-19
15204169-7	2004	We conclude that TF expression increases after BI, but is further increased and persists for a longer duration following ICBT, suggesting that a TF-mediated mechanism may play a role in late thrombosis following ICBT.	icbt	212-216	coagulation factor III, tissue factor	Sus scrofa	145-147
35223279-5	2022	Materials and methods Twenty-two patients with carcinoma of the cervix Stage IB2-IVA receiving ICBT were enrolled in the study.	icbt	95-99	mitogen-activated protein kinase 8 interacting protein 2	Homo sapiens	77-80